Related Experiment Video
Updated: Aug 29, 2025
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
Published on: December 28, 2015
Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy
Paola Muñoz-López1,2, Rosa María Ribas-Aparicio2, Elayne Irene Becerra-Báez1,3
1Unit of Investigative Research on Hemato-Oncological Diseases, Hospital Infantil de México Federico Gómez, Doctor Márquez 162, Mexico City 06720, Mexico.
Abstract:
Cancer remains a public health problem worldwide. Although conventional therapies have led to some excellent outcomes, some patients fail to respond to treatment, they have few therapeutic alternatives and a poor survival prognosis. Several strategies have been proposed to overcome this issue. The most recent approach is immunotherapy, particularly the use of recombinant antibodies and their derivatives, such as the single-chain fragment variable (scFv) containing the complete antigen-binding domains of a whole antibody that successfully targets tumor cells. This review describes the recent progress made with scFvs as a cancer diagnostic and therapeutic tool, with an emphasis on preclinical approaches and their potential use in clinical trials.
Insights
Single-chain fragment variable (scFv) antibodies show promise for cancer diagnosis and therapy. This review highlights preclinical advancements in scFv technology for improved patient outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Biotechnology
Background:
- Cancer poses a significant global health challenge, with conventional treatments often proving ineffective for some patients.
- Limited therapeutic options and poor survival rates necessitate novel treatment strategies for refractory cancers.
Purpose of the Study:
- To review recent advancements in the application of single-chain fragment variable (scFv) antibodies in cancer diagnostics and therapeutics.
- To emphasize the preclinical progress and potential clinical translation of scFv-based cancer strategies.
Main Methods:
- Review of current literature on single-chain fragment variable (scFv) antibody development and application in oncology.
- Focus on preclinical studies demonstrating the efficacy and targeting capabilities of scFvs against tumor cells.
Main Results:
- Single-chain fragment variable (scFv) antibodies are effective tools for targeting tumor cells due to their antigen-binding domains.
- Preclinical research indicates significant potential for scFvs in both diagnosing and treating various cancers.
Conclusions:
- Single-chain fragment variable (scFv) antibodies represent a promising frontier in cancer immunotherapy and diagnostics.
- Further clinical trials are warranted to fully realize the therapeutic potential of scFvs in cancer patient care.
